Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 3/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975165 | 0.83 | USP36 (0.43) | LMNAL3MBTL1GAAUSP36ALDH1A1 | |
| SCHEMBL21176186 | 0.79 | GAA (0.37) | HTTNPC1RAB9AMETAP2METAP1 | |
| SCHEMBL19975279 | 0.78 | MAPT (0.56) | NPC1RAB9AMETAP2METAP1EPHX2 | |
| SCHEMBL19975486 | 0.74 | LMNA (0.44) | NPC1MEN1LMNATSHRKMT2A | |
| SCHEMBL11535411 | 0.71 | MAPT (0.54) | HTTNPC1RAB9AMEN1TSHR | |
| SCHEMBL19974769 | 0.71 | USP36 (0.40) | LMNAGAAUSP36ALDH1A1HSD11B1 | |
| SCHEMBL19975185 | 0.69 | GAA (0.37) | HTTNPC1RAB9AEPHX2MEN1 | |
| SCHEMBL20738625 | 0.68 | USP36 (0.49) | LMNAL3MBTL1GAAUSP36ALDH1A1 | |
| SCHEMBL3677265 | 0.68 | USP36 (0.49) | HTTNPC1RAB9AMEN1LMNA | |
| SCHEMBL19974899 | 0.67 | MAPK1 (0.47) | NPC1RAB9AKMT2AL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | HTT 3380/4885NPC1 753/4885RAB9A 1576/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | HTT 3569/4885NPC1 1213/4885RAB9A 1334/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | HTT 3380/4885NPC1 753/4885RAB9A 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.